Wood 1992.

Methods	Randomised, placebo‐controlled, crossover trial 2X3 cycles
Participants	Country: USA Site: Women recruited from a PMS clinic Recruitment: Women were between the age of 33‐42 years. 8 women randomised, 8 completed Inclusion: Regular menstrual cycles (26‐32 days), ovulating, onset of premenstrual symptoms during the second half of the menstrual cycle with resolution within the first four days after the onset of menstruation Exclusion: Past or present psychiatric disorder, family history of depression in a first degree relative, significant medical or gynaecological disorders
Interventions	Screening: Screening for two to three cycles Placebo run‐in: No Intervention: 20mg fluoxetine every day for 3 cycles then crossover to placebo taken daily for 3 cycles Timing of administration: No details as to when in the cycle medication commenced Summary measures: Data pooled, unable to separate first‐arm data
Outcomes	Calendar premenstrual Experiences, Profile of Mood States, Beck Depression Inventory, STATE‐TRAIT Anxiety Inventory
Notes	Daily symptom rating Funding by National Institute of child health and human development
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, crossover design. "The order in which the subjects received the study drugs was determined according to a preselected randomized list based on the sequential assignment of subject numbers"
Allocation concealment (selection bias)	Unclear risk	Method not reported
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, no details
Incomplete outcome data (attrition bias) All outcomes	Low risk	8/8 women randomised were analysed
Selective reporting (reporting bias)	Unclear risk	Data on adverse events extracted from symptom questionnaire, not solicited separately
Other bias	Unclear risk	Crossover study, no washout period mentioned